• The Effects of Tibolone in Older Postmenopausal Women
  Steven R. Cummings, M.D., Bruce Ettinger, M.D.,Pierre D. Delmas, M.D., Ph.D., Peter Kenemans, M.D., Ph.D., Victoria Stathopoulos, Ph.D., Pierre Verweij, Ph.D., Mirjam Mol-Arts, M.D., Lenus Kloosterboer, Ph.D., Lori Mosca, M.D., Ph.D., M.P.H., Claus Christiansen, M.D., John Bilezikian, M.D., Eduardo Mario Kerzberg, M.D., Susan Johnson, M.D., Jose Zanchetta, M.D., Diederich E. Grobbee, M.D., Ph.D., Wilfried Seifert, Ph.D., and Richard Eastell, M.D., for the LIFT Trial Investigators* N Engl J Med 2008;359:697-708.
   
• Bisphosphonate nephrotoxicity  Mark A. Perazella and Glen S. Markowitz  Kidney International advance online publication, 6 August 2008; doi:10.1038/ki.2008.356
   
• REVIEW ARTICLE: Safety Considerations with Bisphosphonates for the Treatment of Osteoporosis
  William Strampel, Ronald Emkey and Roberto Civitelli Drug Safety 2007; 30 (9): 755-763
   
• Increase in Bone Mass after correction of Vitamin D Insufficiency in Biphosphonate-Treated Patients
  Jordan L Geller, MD, Bei Hu, Ba,  Susan Reed, RN, James Mirocha, MS John S Adams,MD Endocrine Practice  vol 14 no. 3 April 2008 293-297
   
• Relative Effectiveness of Osteoporosis Drugs for Preventing Nonvertebral Fracture
  Suzanne M. Cadarette, PhD; Jeffrey N. Katz, MD, MS; M. Alan Brookhart, PhD; Til Stu¨ rmer, MD, MPH; Margaret R. Stedman, MPH; and Daniel H. Solomon, MD, MPH  Ann Intern Med. 2008;148:637-646.
   
• Nota aclaratoria: Con relación a las publicaciones recientes sobre Fibrilación Auricular asociada al uso de FOSAMAX:  Laboratorios Merck Sharp  & Dhome -México
   
• Screening for Osteoporosis in Men: A Clinical Practice Guideline from the American College of Physicians
  Amir Qaseem, MD, PhD, MHA; Vincenza Snow, MD; Paul Shekelle, MD, PhD; Robert Hopkins Jr., MD; Mary Ann Forciea, MD; and Douglas K. Owens, MD, MS, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians Ann Intern Med. 2008;148:680-684.
   
• ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults
  Eric J. MacLaughlin and Cynthia L. Raehl Am J Health-Syst Pharm. 2008; 65:343-57
   
• Use of Alendronate and Risk of Incident Atrial Fibrillation in Women
  Susan R. Heckbert, MD, PhD; Guo Li, MS; Steven R. Cummings, MD; Nicholas L. Smith, PhD; Bruce M. Psaty, MD, PhD  Arch Intern Med. 2008;168(8):826-831
   
• Osteoprotegerin, Thiazolidinediones Treatment, and Silent Myocardial Ischemia in Type 2 Diabetic Patients
  ARIANE SULTAN, MD ANTOINE AVIGNON, MD FLORENCE GALTIER, MD CHRISTOPHE PIOT, MD DENIS MARIANO-GOULART, MD ANNE MARIE DUPUY, MD JEAN PAUL CRISTOL, MD   DIABETES CARE, VOLUME 31, NUMBER 3, MARCH 2008
   
• Bone Fractures and Hypoglycemic Treatment in Type 2 Diabetic Patients.A case-control study
  MATTEO MONAMI, MD, PHD BARBARA CRESCI, MD ANGELA COLOMBINI, MD LAURA PALA, MD DANIELA BALZI, MD FRANCESCA GORI, MD VERONICA CHIASSERINI, MD NICCOL `O MARCHIONNI, MD CARLO MARIA ROTELLA, MD  EDOARDO MANNUCCI, MD Diabetes Care 31:199–203, 2008
   
• The Peroxisome Proliferator-Activated Receptor- Agonist Rosiglitazone Decreases Bone Formation and
  Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial.  Andrew Grey, Mark Bolland, Greg Gamble, Diana Wattie, Anne Horne, James Davidson, and Ian R. Reid, J Clin Endocrinol Metab 92: 1305–1310,
  2007

• Use of Thiazolidinediones and Fracture Risk Christian Meier, MD; Marius E. Kraenzlin, MD; Michael Bodmer, MD;
  Susan S. Jick, DSc; Hershel Jick, MD; Christoph R. Meier, PhD  Arch Intern Med. 2008;168(8):820-825
   
• Review: Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues Kathryn M. Thrailkill, Charles K. Lumpkin, Jr., R. Clay Bunn, Stephen F. Kemp, and John L. Fowlkes. Am J Physiol Endocrinol Metab 289: E735–E745, 2005.
   
• Editorial: Bona Fide Genetic Associations with Bone Mineral Density
  Joel N. Hirschhorn, M.D., Ph.D., and Luigi Gennari, M.D., Ph.D. N Engl J Med 10.1056/nejme0803046
   
• Multiple Genetic Loci for Bone Mineral Density and Fractures
  Unnur Styrkarsdottir, Ph.D., Bjarni V. Halldorsson, Ph.D.,Solveig Gretarsdottir, Ph.D., Daniel F. Gudbjartsson, Ph.D.,
  G. Bragi Walters, B.Sc., Thorvaldur Ingvarsson, M.D., Ph.D.,Thorbjorg Jonsdottir, B.Sc., Jona Saemundsdottir, B.Sc., Jacqueline R. Center, M.B., B.S., Ph.D., Tuan V. Nguyen, Ph.D., Yu Bagger, M.D., Jeffrey R. Gulcher, M.D., Ph.D., John A. Eisman, M.B., B.S., Ph.D., Claus Christiansen, M.D., Gunnar Sigurdsson, M.D., Ph.D., Augustine Kong, Ph.D., Unnur Thorsteinsdottir, Ph.D., and Kari Stefansson, M.D., Ph.D.  N Engl J Med 2008;358.
   

• Position Paper:
  European guidance for the diagnosis and management of osteoporosis in postmenopausal women
  J. A. Kanis, N. Burlet, C. Cooper, P. D. Delmas, J.-Y. Reginster, F. Borgstrom, R. Rizzoli,  Osteoporos Int (2008) 19:399–428 DOI 10.1007/s00198-008-0560-z
  on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
   

• FRAX™ and the Assessment of Fracture Probability: An Introduction
  John A. Kanis, Anders Oden, Helena Johansson, and Eugene McCloskey  IBMS BoneKEy. 2008 March;5(3):114-117 http://www.bonekey-ibms.org/cgi/content/full/ibmske;5/3/114 doi: 10.1138/20080305
  WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom

• Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure Robert R Recker, , Pierre D Delmas, , Johan Halse, , Ian R Reid, , Steven Boonen, , Pedro A García-Hernandez, , Jerzy Supronik, , E Michael Lewiecki, , Luis Ochoa, , Paul Miller, , Huilin Hu, , Peter Mesenbrink, , Florian Hartl, , Juerg Gasser, , Erik F Eriksen, Journal of Bone and Mineral Research,  January 2008:23:6-16
   

• Correlation of Obesity and Osteoporosis: Effect of Fat Mass on the Determination of Osteoporosis Lan-Juan Zhao, , Hui Jiang, , Christopher J Papasian, , Dev Maulik, , Betty Drees, , James Hamilton, , Hong-Wen Deng, Journal of Bone and Mineral Research, January 2008:23:17-29
   

• Use of Oral Bisphosphonates and the Risk of Aseptic Osteonecrosis: A Nested Case-Control Study Mahyar Etminan, Kevin Aminzadeh, Ian R. Matthew and James M. Brophy  The Journal of Rheumatology 2008; 35:3
   

• Direct costs of osteoporosis and hip fracture: an analysis for the Mexican healthcare system. P. Clark , F. Carlos , C. Barrera , J. Guzman ,A. Maetzel , P. Lavielle , E. Ramirez , V.Robinson,R. Rodriguez-Cabrera , J. Tamayo , P. Tugwell . Osteoporos Int DOI 10.1007/s00198-007-0496-8  (Diciembre 2007)
   

• Development and Internal Validation of the Male Osteoporosis Risk Estimation Score. Angela J. Shepherd, Alvah R. Cass, Carol A. Carlson, Laura Ray, Ann Fam Med 2007;5:540-546. 10.1370/afm.753.
   

• Individualization of osteoporosis risk . T. V. Nguyen  Osteoporos Int (2007) 18:1153–1156
   

• Vertebral dimensions as risk factor of vertebral fracture in osteoporotic patients: a systematic literature review. A. Ruyssen-Witrand , L. Gossec , S. Kolta ,M. Dougados , C.Roux Osteoporos Int (2007) 18:1271–1278 
   

• Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club
  J. J. Body, P. Bergmann, S. Boonen , Y. Boutsen, J. P. Devogelaer, S. Goemaere, J. Y. Reginster, S. Rozenberg, J. M. Kaufman
  Osteoporos Int (2007) 18:1439–1450
   

• Incidence of second hip fractures. A population-based study 
  E. Lönnroos, H. Kautiainen, P. Karppi, S. Hartikainen, I. Kiviranta, R. Sulkava 
  Osteoporos Int (2007) 18:1279–1285
   

• Excess mortality following hip fracture: the role of underlying health status
  A. N. A. Tosteson, D. J. Gottlieb, D. C. Radley, E. S. Fisher, L. J. Melton III
  Osteoporos Int (2007) 18:1463-1472
   

• Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis
  J. P. Devogelaer, J. P. Brown , P. Burckhardt , P. J. Meunier , S. Goemaere , K. Lippuner , J. J. Body ,G. Samsioe , D. Felsenberg , T. Fashola , L. Sanna ,C. E. Ortmann , U. Trechsel ,J. Krasnow , E. F. Eriksen , P. Garnero.
  Osteoporos Int (2007) 18:1211–1218
   

• Review :  Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?
  E. Seeman  Bone 41 (2007) 308–317 ,
   

• Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture  Kenneth W. Lyles, M.D., Cathleen S. Colón-Emeric, M.D., M.H.Sc., Jay S. Magaziner, Ph.D., Jonathan D. Adachi, M.D., Carl F. Pieper, D.P.H., Carlos Mautalen, M.D., Lars Hyldstrup, M.D., D.M.Sc., Chris Recknor, M.D., Lars Nordsletten, M.D., Ph.D., Kathy A. Moore, R.N., Catherine Lavecchia, M.S., Jie Zhang, Ph.D., Peter Mesenbrink, Ph.D., Patricia K. Hodgson, B.A., Ken Abrams, M.D., John J. Orloff, M.D., Zebulun Horowitz, M.D., Erik  Fink Eriksen, M.D., D.M.Sc., and Steven Boonen, M.D., Ph.D., for the HORIZON Recurrent Fracture Trial*
  N Engl J Med 2007;357.   September 17, 2007.
   

• Hip fractures in users of first- vs. second-generation bisphosphonates  M. Mamdani  A. Kopp  G. Hawker
  Osteoporosis Int  DOI 10.1007/s00198-007-0446-5
   

• Cultural adaptation and validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO) in a Mexican population  Esperanza Ramírez Pérez, Patricia Clark, Niels H. Wacher, Mario H. Cardiel , Ma. del Pilar Diez García Clin Rheumatol  DOI 10.1007/s10067-007-0661-7, 2007
   

• Cost-effectiveness of Bone Densitometry Followed by Treatment of Osteoporosis in Older Men John T. Schousboe, MD, MS Brent C. Taylor, PhD, MPH, Howard A. Fink, MD, MPH, Robert L. Kane, MD, Steven R. Cummings, MD , Eric S. Orwoll, MD, L. Joseph Melton III, MD, MPH, Douglas C. Bauer, MD, Kristine E. Ensrud, MD, MPH   JAMA, August 8, 2007—Vol 298, No. 6, 629-637
   

• Review : Osteoporosis in Patients With Diabetes Mellitus Lorenz C Hofbauer, Carolin C Brueck, Shiv K Singh, and Harald Dobnig J Bone Miner Res 2007;22:1317–1328. Published online on May 14, 2007; doi: 10.1359/JBMR.070510

•  

• Decision Rules for Selecting Women for Bone Mineral Density Testing: Application in Postmenopausal Women Referred to a Bone Densitometry Unit
  Dolores Martinez-Aguila, Carmen Gomez-Vaquero, Antoni Rosadilla, Montserrat Romera, Javier Narvaez  and Joan M. Nolla. J Rheumatol 2007;34:1307–12)
   

• Technical White Paper: Bone Densitometry  June Hawkinson, BS, RT(R), Julie Timins, MD, Dennis Angelo, MS,Margaret Shaw, RT(R), Russell Takata, MPH, Frances Harshaw, BS,
   J Am Coll Radiol 2007;4:320-327.
   

• Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
     Dennis M. Black y cols New England Journal of Medicine Volume 356:1809-1822 May 3, 2007 Number 18
   

• Implementation of a Mandatory Rheumatology Osteoporosis Consultation in Patients With Low-Impact Hip Fracture.
  Anne-Marie Quintos-Macasa, MD, Robert Quinet, MD, Malik Spady, MD, Jerald Zakem, MD,William Davis, MD, Yamini Menon, MD, Leonard Serebro, MD, and M. A. Krousel-Wood, MD, MSPH
  J Clin Rheumatol 2007;13: 70–72
   

• Risedronate Reduces Postoperative Bone Resorption After Cementless Total Hip Arthroplasty
  S. Yamasaki, K. Masuhara, K. Yamaguchi, T. Nakai, T. Fuji, Y. Seino  Osteoporos Int (2007) 18:1009–1015
   

• Osteoporosis
  Lee S. Simon, MD Rheum Dis Clin N Am 33 (2007) 149–176

                                Asociación Mexicana de Metabolismo Oseo y Mineral AC
                                Durango 269 oficina 6 ,3er piso  Colonia Roma, Delegación Cuauhtémoc
                                 México DF CP 06700 Tel y FAX: 01 (55) 55-11-72-60  
                                             web: http://www.ammom.com.mx
                                            e-mail: ammomcentral@prodigy.net.mx
  

                                    Responsable del mantenimiento de esta página:
                                    Dr. Fidencio Cons Molina  fcons@ammom.com.mx